Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetylcysteine versus bromhexine in outpatients with COVID-19
IRCT20220302054167N1Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of acetylcysteine and bromhexine in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Duration of recovery, Duration of hospitalization and 1 more. Started Mar 2022; status: completed.
02
Drugs
acetylcysteinebromhexine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20220302054167N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220302054167N1.